Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemo Delay After Surgery for Ovarian Cancer

Gynecol Oncol; ePub 2016 Nov 28; Seagle, et al

Chemotherapy delays of >35 days after primary debulking surgery for ovarian cancer was associated with a 7% increased hazard of death, a recent study found, while consistently starting chemotherapy between 21 and 35 days achieved an overall survival (OS) benefit. This observational retrospective cohort of women with ovarian cancer was performed with the 1998-2011 National Cancer Data Base. Researchers found:

  • 58.1% (26,149/45,001) women experienced chemotherapy delay.
  • Odds for chemotherapy delay were significantly higher for older or sicker women, women with endometrioid or mucinous histology, lower stage or grade disease, and uninsured or low-income women.
  • Chemotherapy delay >35 days from surgery was associated with a 7% increased hazard of death.
  • Relative hazard of death was lowest between 25 and 29 days after surgery.

Citation:

Seagle BLL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S. Chemotherapy delay after primary debulking surgery for ovarian cancer. [Published online ahead of print November 28, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.11.022.